Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04011722




Registration number
NCT04011722
Ethics application status
Date submitted
4/07/2019
Date registered
8/07/2019
Date last updated
20/02/2024

Titles & IDs
Public title
Portico NG Approval Study
Scientific title
Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Secondary ID [1] 0 0
ABT-CIP-10308
Secondary ID [2] 0 0
ABT-CIP-10297
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Symptomatic Severe Aortic Stenosis 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
Treatment: Devices - Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System

Experimental: Portico™ NG (Navitor) valve, FlexNav™ Delivery System - Portico ™ NG (Navitor) valve implantation with the new generation Portico NG (Navitor) valve (23mm, 25mm, 27mm and 29mm sizes), and the second-generation FlexNav Delivery system (small and large), Portico™ NG (Navitor) Loading System(s) (small and large).

Experimental: Navitor Titan Valve - Navitor Titan Valve (35mm) implantation with the large FlexNav Delivery system and Navitor Loading System - LG+.


Treatment: Devices: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Treatment: Devices: Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary safety endpoint is all-cause mortality
Timepoint [1] 0 0
at 30 days
Primary outcome [2] 0 0
Primary effectiveness endpoint is moderate or greater paravalvular leak
Timepoint [2] 0 0
at 30 days
Secondary outcome [1] 0 0
Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications
Timepoint [1] 0 0
at 30 days

Eligibility
Key inclusion criteria
Key

1. Subjects must have a Society of Thoracic Surgeons (STS) score of =7% OR documented
heart team agreement of high or extreme risk for surgical aortic valve replacement due
to frailty or co-morbidities not captured by the STS score.

2. Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart
Association) Functional Classification of II, III, or IV.

3. Subject has senile degenerative aortic valve stenosis with echo-derived criteria,
defined as: aortic valve area (AVA) of = 1.0 cm2 (or indexed EOA (effective orifice
area) = 0.6 cm2/m2) AND mean gradient =40 mmHg or peak jet velocity = 4.0 m/s or
doppler velocity index (DVI) =0.25. (Qualifying AVA baseline measurement must be
within 90 days prior to informed consent).

4. Aortic annulus diameter of 19-30mm and ascending aorta diameter for the specified
valve size listed in the IFU (Instructions For Use), as measured by CT (Computed
Tomography)

Key
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as
evidenced on 12 Lead ECG) within 30 days prior to index procedure.

2. Any percutaneous coronary or peripheral interventional procedure performed within 30
days prior to index procedure.

3. Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL),
thrombocytopenia (platelet count <50,000 cells/mm³). History of bleeding diathesis or
coagulopathy

4. Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that
would preclude anticoagulation

5. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA)
or a transient ischemic attack (TIA).

6. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
aortic regurgitation 3-4+).

7. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic
ring, severe circumferential mitral annular calcification (MAC) which is continuous
with calcium in the left ventricular outflow tract (LVOT), severe (greater than or
equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary
compromise.

8. Minimum access vessel diameter of <5.0mm for small FlexNav™ Delivery System and <5.5
mm for large FlexNav™ Delivery System

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/09/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
Accrual to date
Final
333
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
St. Andrew's Hospital - Adelaide
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Utah
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
Denmark
State/province [18] 0 0
Copenhagen
Country [19] 0 0
Italy
State/province [19] 0 0
Lombard
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Northern Ireland
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Abbott Medical Devices
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the
next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the
rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak
at 30 days in a high or extreme surgical risk patient population to support CE (Conformité
Européenne) Mark and FDA approval.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04011722
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04011722